Teva long-acting antipsychotic Uzedy gains indication for bipolar disorder

 

• FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.1
• UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults.1
• This approval marks a significant step towards addressing the unmet needs of people living with BD-I and schizophrenia, underscoring Teva’s ongoing commitment to drive new advances in neuroscience.

https://www.tevapharm.com/news-and-media/latest-news/fda-approves-expanded-indication-for-uzedy-risperidone-extended-release-injectable-suspension-as-a-tre/